Research Background
BPC-157 is a pentadecapeptide composed of 15 amino acid residues, originally isolated as a partial sequence of the body protection compound (BPC) found in human gastric juice. The compound has been the subject of extensive preclinical research, particularly in rodent models examining tissue regeneration pathways, angiogenic response, and inflammatory modulation.
The compound is widely used as a reference standard in peptide research and as an experimental tool in in-vitro assays investigating fibroblast migration, tendon-to-bone outgrowth modelling, and nitric oxide pathway studies. It is stable in gastric acid — a characteristic that makes it a useful comparator compound in oral peptide stability research.
EmirG / R supplies BPC-157 exclusively as a research reagent. No therapeutic or consumption claims are made. Researchers are expected to follow appropriate biosafety and institutional protocols in all work involving this compound.
Assay & Purity Data
Each batch of EmirG / R BPC-157 is independently assayed by an ISO-17025 aligned testing facility. The current stocked batch (EG-4451) has the following released specifications:
- HPLC purity (UV 214nm): 99.4%
- Mass spectrometry: confirmed — 1419.5 Da observed vs 1419.53 Da theoretical
- Water content (Karl Fischer): < 5.2%
- Acetate content: < 14%
- Bacterial endotoxin: below detection
- Appearance: white to off-white lyophilised cake
Full Certificate of Analysis is available as a downloadable PDF on the CoA archive or by scanning the QR code printed on the vial.
Handling & Storage
Storage (unopened): Store lyophilised powder at −20°C, protected from light and moisture. Stable for 24 months from date of assay release when stored correctly.
Reconstitution: Reconstitute in bacteriostatic water for research purposes. Do not agitate forcefully — dispense solvent against the vial wall. Allow the powder to dissolve without shaking.
Post-reconstitution: Refrigerate reconstituted solution at 2–8°C. Use within a research-defined stability window appropriate to your protocol.
Biosafety: Handle in accordance with institutional BSL-1 or equivalent research protocols. Use appropriate PPE. Dispose of vials and materials according to local biochemical waste regulations.
Literature References
Selected peer-reviewed research involving BPC-157 as a study compound or reference material:
- [01] Sikiric P, et al. — Current Pharmaceutical Design, cumulative reviews on BPC-157 preclinical profile.
- [02] Huang T, et al. — Role of BPC-157 in tendon outgrowth model systems. J Applied Physiol.
- [03] Chang C-H, et al. — Effect on fibroblast migration in wound healing assay. Molecules.
- [04] Seiwerth S, et al. — BPC-157 and angiogenesis. Current Medicinal Chemistry.
- [05] Gwyer D, et al. — Review of therapeutic peptide candidates. Cell Tissue Res.
References provided for bibliographic context. EmirG / R does not endorse any specific interpretation of cited research. Consult primary sources directly.
Compliance Notice
BPC-157 is not a scheduled substance under the UK Misuse of Drugs Act 1971. It is not an approved medicine under the Human Medicines Regulations 2012. EmirG / R supplies the compound strictly for research use, in alignment with MHRA guidance on research chemical supply.
By purchasing this product, the customer confirms they are:
- 18 years of age or older
- Purchasing the compound for bona-fide research purposes only
- Not administering the compound to humans or animals
- Operating within appropriate research and biosafety protocols
Any use outside of controlled research settings is the sole responsibility of the purchaser. EmirG / R will not supply customers found to be misrepresenting intended use.